1. Home
  2. ZGN vs NUVB Comparison

ZGN vs NUVB Comparison

Compare ZGN & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ermenegildo Zegna N.V.

ZGN

Ermenegildo Zegna N.V.

HOLD

Current Price

$10.72

Market Cap

2.7B

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$8.43

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZGN
NUVB
Founded
1910
2018
Country
Italy
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.9B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ZGN
NUVB
Price
$10.72
$8.43
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
9
Target Price
$10.98
$10.56
AVG Volume (30 Days)
515.0K
5.6M
Earning Date
09-05-2025
11-03-2025
Dividend Yield
1.34%
N/A
EPS Growth
N/A
N/A
EPS
0.43
N/A
Revenue
$2,248,050,499.00
$26,748,000.00
Revenue This Year
N/A
$609.55
Revenue Next Year
$4.87
$197.91
P/E Ratio
$24.10
N/A
Revenue Growth
N/A
1137.19
52 Week Low
$6.05
$1.54
52 Week High
$11.00
$9.75

Technical Indicators

Market Signals
Indicator
ZGN
NUVB
Relative Strength Index (RSI) 56.42 50.42
Support Level $10.29 $8.04
Resistance Level $10.73 $9.10
Average True Range (ATR) 0.26 0.45
MACD 0.01 -0.20
Stochastic Oscillator 76.19 20.11

Price Performance

Historical Comparison
ZGN
NUVB

About ZGN Ermenegildo Zegna N.V.

Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. The company operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment, and the Tom Ford Fashion segment. The company generates the majority of its revenue from the Zegna segment.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Share on Social Networks: